pirtobrutinib,rituximab,venetoclax
roche,abbvie,eli lilly
['lymsm', 'bruin', 'leusm']
#aacr23 attendees - see results from the phase 1/2 bruin study, investigating a highly selective, non-covalent (reversible) btk inhibitor in richter transformation. #leusm #lymsm view the presentation details here: 
Dedicated to communicating the latest science & innovation from Loxo@Lilly. Tweets intended for US oncology HCPs. See our community guidelines: https://t.co/1q8vAe63mK